GeoVax to Discuss BARDA Contract Termination at Emerging Growth Conference

Biotechnology company GeoVax Labs will provide a comprehensive update on its COVID-19 vaccine program during the upcoming Emerging Growth Conference, focusing on the recent termination of its contract with the Biomedical Advanced Research and Development Authority (BARDA).

CEO David Dodd is scheduled to present at 3:40 pm ET on April 16, 2025, offering investors and interested parties an opportunity to gain insights into the company's current research and development strategies. The presentation will specifically address the unexpected contract termination and its potential implications for the company's lead clinical program, GEO-CM04S1.

The GEO-CM04S1 vaccine is currently being evaluated in three Phase 2 clinical trials, targeting unique patient populations including immunocompromised individuals, patients with chronic lymphocytic leukemia, and those seeking more robust booster protection after initial mRNA vaccinations.

Despite the BARDA contract termination, GeoVax remains committed to advancing its COVID-19 vaccine research. The company's strategic approach focuses on developing vaccines for patient groups who have not been adequately served by existing COVID-19 vaccination technologies.

In addition to its COVID-19 program, GeoVax continues to progress its oncology research, including the Gedeptin® gene-directed therapy for advanced head and neck cancers, and is developing a vaccine targeting Mpox and smallpox.

The conference presentation represents a critical opportunity for GeoVax to provide transparency about its ongoing research, address potential investor concerns regarding the BARDA contract, and outline the company's forward-looking strategy in vaccine development.